Table 1.
Patient Characteristics and Prevalence of Possible Contraindications to Nirmatrelvir/Ritonavir
| Highest Acuity of Illness | P Value | ||||
|---|---|---|---|---|---|
| Outpatient | Inpatient | ICU | Mortality | ||
| (n = 59 869), No. (%) | (n = 3818), No. (%) | (n = 1339), No. (%) | (n = 981), No. (%) | ||
| Use of medications dependent on CYP3A for clearance | 2298 (3.8) | 309 (8.1) | 108 (8.1) | 117 (11.9) | <.001 |
| Use of medications that induce CYP3A | 256 (0.4) | 28 (0.7) | 12 (0.8) | 12 (1.2) | <.001 |
| Severe renal impairmenta | 1268 (2.1) | 419 (10.9) | 174 (13.0) | 231 (23.5) | <.001 |
| Severe hepatic impairmenta | 284 (0.4) | 93 (2.4) | 61 (4.6) | 42 (4.3) | <.001 |
| Age <12 y | 4671 (7.8) | 49 (1.3) | 21 (1.6) | 0 (0.0) | <.001 |
| Weight <40 kg and age <18 y | 3702 (6.2) | 41 (1.3) | 17 (1.2) | 0 (0.0) | <.001 |
| Individual patients with 1+ contraindicationb | 8403 (14.0) | 787 (20.6) | 306 (22.9) | 334 (35.1) | <.001 |
Abbreviations: FDA, Food and Drug Administration; ICU, intensive care unit.
a
The FDA does not recommend use of Paxlovid in patients with severe renal and hepatic impairment due to a lack of pharmacokinetic or safety data.
b
Patients with multiple contraindications were counted once.